Humalog Shortage Update: What Patients Need to Know in 2026

The 2024 Humalog shortage caught millions of diabetes patients off guard. Eli Lilly, the sole manufacturer of Humalog, acknowledged manufacturing delays and ultimately discontinued the 3 mL vial format — leaving patients scrambling to find alternative forms or brands. If you've been following the shortage or are worried about Humalog availability in 2026, here's everything you need to know.

What Is the Current Status of the Humalog Shortage in 2026?

As of 2026, Humalog is not listed as an active nationwide shortage by the FDA or the American Society of Health-System Pharmacists (ASHP). The national supply of Humalog 10 mL U-100 vials and all KwikPen formats (U-100 and U-200) has largely stabilized since the acute shortage period of 2024.

However, some local pharmacies may still experience temporary stockouts. The 3 mL vial size was permanently discontinued and is no longer available from any source. Patients who relied on the 3 mL format need to use 10 mL vials or switch to prefilled pens.

Timeline: What Happened With the Humalog Shortage?

Here's a summary of how the Humalog shortage unfolded:

• Early 2024: Eli Lilly publicly announces a shortage of Humalog and generic insulin lispro vials, citing "the dynamic nature of insulin supply and demand, coupled with brief delays in manufacturing."
• Spring–Summer 2024: Widespread pharmacy stockouts reported. Patients with Type 1 diabetes — who have no alternative to insulin — are most severely affected. Lilly clarifies that KwikPens and 10 mL vials remain in production.
• Late 2024: Lilly permanently discontinues the 3 mL vial format. Supply of 10 mL vials and pens begins to recover and distribution stabilizes.
• 2025: National supply largely normalized. Localized stockouts persist at some pharmacies.
• 2026: No active FDA/ASHP shortage listing. Humalog 10 mL vials and KwikPens generally available. Some pharmacy-level stockouts remain possible.

What Caused the 2024 Humalog Shortage?

Several factors contributed to the 2024 shortage:

• Manufacturing delays. Eli Lilly cited brief manufacturing delays that disrupted the supply chain for vial formats.
• Production reallocation. Lilly's manufacturing capacity was under strain partly due to enormous demand for GLP-1 drugs like Mounjaro (tirzepatide), which competes for production resources and facilities.
• Concentrated market. Just three companies (Lilly, Novo Nordisk, and Sanofi) supply the vast majority of the world's insulin. Any disruption at one manufacturer has broad consequences.
• Demand surge. The price caps introduced in 2023 may have increased demand as more patients who had been rationing insulin could suddenly afford full doses.

How the 2023 Price Cuts Changed the Landscape

In March 2023, Eli Lilly announced a 70% reduction in Humalog's list price, bringing the brand-name vial from as much as $274 per vial down to approximately $72–$86. The company also launched the Lilly Insulin Value Program, capping out-of-pocket costs at $35 per month for all Lilly insulins regardless of insurance status.

Additionally, the authorized generic insulin lispro (non-branded Humalog) was priced at just $25 per 10 mL vial. For Medicare patients, the Inflation Reduction Act capped insulin costs at $35/month under Part D.

What Should Patients Do Right Now?

Even though the national Humalog supply is largely stable, patients should be proactive:

1. Know your alternatives. Talk to your doctor now about which rapid-acting insulins you could switch to if Humalog becomes unavailable again. Admelog, NovoLog, and Apidra are all solid options.
2. Request refills early. Refill as soon as your insurance allows — typically when you have 7–10 days of supply remaining. Consider asking for a 90-day supply if your plan allows it.
3. Ask about the generic. Generic insulin lispro (authorized by Lilly) is identical to Humalog and available for $25/vial. It may have better stock availability at some pharmacies than the brand-name version.
4. Use medfinder to locate stock. medfinder calls pharmacies near you to find which ones have Humalog in stock — saving you hours of phone calls.

Is Humalog Safe to Use? Has the Shortage Affected Quality?

Yes, Humalog is safe to use. The shortage was a supply issue — manufacturing and distribution delays — not a quality or safety concern. All Humalog and insulin lispro products currently on pharmacy shelves have passed Lilly's quality control standards. If you find expired or abnormal-looking insulin (cloudy, discolored, or containing particles), do not use it and contact your pharmacist. For more background on what caused availability issues, see our full explainer on why Humalog is hard to find.